Form 8-K - Current report:
SEC Accession No. 0001999371-25-021283
Filing Date
2025-12-29
Accepted
2025-12-29 16:44:21
Documents
21
Period of Report
2025-12-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tonix-8k_122925.htm   iXBRL 8-K 37308
2 PLACEMENT AGENCY AGREEMENT ex1-01.htm EX-1.01 108106
3 FORM OF PRE-FUNDED WARRANT ex4-01.htm EX-4.01 85301
4 OPINION OF BROWNSTEIN HYATT FARBER SCHRECK, LLP ex5-01.htm EX-5.01 15632
5 OPINION OF LOWENSTEIN SANDLER LLP ex5-02.htm EX-5.02 11181
6 FORM OF SECURITIES PURCHASE AGREEMENT ex10-01.htm EX-10.01 243477
7 PRESS RELEASE ex99-01.htm EX-99.01 35991
11 GRAPHIC ls-logo.jpg GRAPHIC 4319
12 GRAPHIC tonix-logo.jpg GRAPHIC 3155
13 GRAPHIC brownstein-logo.jpg GRAPHIC 2933
  Complete submission text file 0001999371-25-021283.txt   850626

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE tnxp-20251229.xsd EX-101.SCH 2990
9 XBRL LABEL FILE tnxp-20251229_lab.xml EX-101.LAB 34239
10 XBRL PRESENTATION FILE tnxp-20251229_pre.xml EX-101.PRE 22342
23 EXTRACTED XBRL INSTANCE DOCUMENT tonix-8k_122925_htm.xml XML 3071
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 251609743
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)